Sino Biopharma reports Phase I data showing TQC3721 dry powder inhaler boosts COPD lung function in dose-ranging trial

• Sino Biopharmaceutical reported Phase I data for its inhaled COPD drug candidate TQC3721, already presented at ERS 2026.
• In a placebo-controlled trial, the dry-powder formulation improved lung function in COPD patients with a safety profile similar to placebo.
• An open-label Phase I combination study showed clinically meaningful lung-function gains versus an indacaterol/glycopyrronium comparator in early readouts.
• Completed results supported moving toward a fixed-dose TQC3721 plus LAMA product, positioning it as a triple-action dual bronchodilator program.
• The company also highlighted a separate nebulized TQC3721 program already in Phase III in China with breakthrough-therapy status.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sino Biopharmaceutical Limited published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260907-12323521), on September 07, 2026, and is solely responsible for the information contained therein.